| Autor: |
Li X; Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA. xiaofan.li@mssm.edu., Slesinger PA; Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA. paul.slesinger@mssm.edu. |
| Jazyk: |
angličtina |
| Zdroj: |
Current topics in behavioral neurosciences [Curr Top Behav Neurosci] 2022; Vol. 52, pp. 119-155. |
| DOI: |
10.1007/7854_2020_187 |
| Abstrakt: |
Metabotropic GABA B receptors (GABA B Rs) mediate slow inhibition and modulate synaptic plasticity throughout the brain. Dysfunction of GABA B Rs has been associated with psychiatric illnesses and addiction. Drugs of abuse alter GABA B receptor (GABA B R) signaling in multiple brain regions, which partly contributes to the development of drug addiction. Recently, GABA B R ligands and positive allosteric modulators (PAMs) have been shown to attenuate the initial rewarding effect of addictive substances, inhibit seeking and taking of these drugs, and in some cases, ameliorate drug withdrawal symptoms. The majority of the anti-addiction effects seen with GABA B R modulation can be localized to ventral tegmental area (VTA) dopamine neurons, which receive complex inhibitory and excitatory inputs that are modified by drugs of abuse. Preclinical research suggests that GABA B R PAMs are emerging as promising candidates for the treatment of drug addiction. Clinical studies on drug dependence have shown positive results with GABA B R ligands but more are needed, and compounds with better pharmacokinetics and fewer side effects are critically needed.
(© 2020. Springer Nature Switzerland AG.) |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
